FDA extends approval in Daklinza (daclatasvir) plus Sovaldi (sofosbuvir) to genotypes 1 and 3 chronic hepatitis C- BMS
Hepatology Drug News today
Bristol-Myers Squibb announced that the FDA has expanded approval of Daklinza (daclatasvir, 60 mg), in combination with Sovaldi (sofosbuvir) with...
Phase III pivotal study of defibrotide for hepatic veno-occlusive disease is published in Blood.- Jazz Pharma
Hepatology Drug News 5 days ago
Jazz Pharmaceuticals plc announced that data from the phase III pivotal study of defibrotide were published online in BLOOD, the...
FDA approves Zepatier (elbasvir and grazoprevir) to treat chronic hepatitis C virus genotype (GT) 1 or GT4 infection, with or without ribavirin -Merck Inc.
Hepatology Drug News 8 days ago
Merck Inc. announced that the FDA has approved Zepatier (elbasvir and grazoprevir) for the treatment of adult patients with chronic...
FDA approves Daklinza (daclatasvir) + sofosbuvir for cirrhosis patients, HIV patients and post liver transplant patients co-infected with Hepatitis C.- BMS
Infectious Diseases Drug News 8 days ago
Bristol-Myers Squibb Company (BMS) has announced that the European Commission has approved Daklinza (daclatasvir) for the treatment of chronic hepatitis...
Phase III METIV-HCC trial data for ARQ 197 (tivantinib) in hepatocellular carcinoma confirms phase II results- ArQule
Oncology Drug News 26/01/16
ArQule announced that an analysis of preliminary baseline tumor MET status of patients screened in the phase III METIV-HCC trial...
- Endoscopic Sclerotherapy (ES) and Endoscopic Ligation (EL) were accepted in the treatment of esophageal varices bleeding in patients with liver cirrhosis. EL seemed to be superior to ES. If EL was difficult then ES should be performed.
Read more about Pegasys 135mcg and 180mcg solution for injection in Pre-filled Syringe/Pre-filled PenPEGASYS 135MCG AND 180MCG SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE/PRE-FILLED PEN
Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure.9 days ago - Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure.
Hepatic veno-occlusive disease, also called sinusoidal obstruction syndrome (VOD/SOS), is a potentially life-threatening complication of hematopoietic stem cell transplantation (HSCT). Untreated ...
Antibody Levels and Protection After Hepatitis B Vaccine: Results of a 30-Year Follow-up Study and Response to a Booster Dose.Thu 21 Jan 2016 - Antibody Levels and Protection After Hepatitis B Vaccine: Results of a 30-Year Follow-up Study and Response to a Booster Dose.
Background: The duration of protection in children and adults resulting from hepatitis B vaccination is unknown. In 1981, we immunized a cohort of 1578 Alaska Native adults and children from 15 ...
EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosisApr 2015
These Clinical Practice Guidelines (CPGs) have been developed by a panel of experts chosen by the..
These EASL Recommendations on Treatment of Hepatitis C are intended to assist physicians and..
After completing this module, you should be able to: interpret abnormal liver function tests, evaluate a patient with abnormal liver function tests, and diagnose the most likely cause of abnormal...
After completing this module, you should: be aware that patients who are symptomatic often have a completely different pattern of change to their liver function tests to those who are...
After completing this module you should be able to: recognise different patterns of abnormal liver function tests associated with alcoholic liver disease, assess the severity of alcoholic liver disease from...
Association Between Autologous Transfusion and Recurrence Among Patients With HCC After Resection (AT/HCC)Fri 01 Jan 2016
This prospective study aims to determine whether autotransfusion of red blood cells salvaged during liver resection is associated with the recurrence of hepatocellular ...
Effects of Empagliflozin on Liver Fat Content, Energy Metabolism and Body Composition in Patients With Type 2 Diabetes (EmLiFa)Tue 01 Dec 2015
The effects of empagliflozin treatment on hepatocellular lipid content, liver energy metabolism and body composition will be investigated in a multicentre, prospective, placebo-controlled, ...